Clinical Trial Detail

NCT ID NCT02846376
Title Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hackensack University Medical Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Ipilimumab

Ipilimumab + Nivolumab

Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST